Cannabis News

Hawaii Lawmakers Approve Bill To Create Psychedelics Task Force Charged With Studying Psilocybin And MDMA

Published

3 weeks ago

April 9, 2026

admin

Another Hawaii House committee has passed the Senate-passed bill creating a psychedelic task force responsible for analyzing and making policy recommendations about providing access to breakthrough therapies like psilocybin and MDMA.

The House Finance Committee advanced the legislation to Sen. Chris Lee (D) on a 15-0 vote Tuesday. The measure, which passed the Senate last month by a 24-0 vote, will next go to the House floor before returning to the Senate for that chamber to consider final amendments.

The bill would create Creative Mental Health Therapy, a two-year review of the current scientific literature, supporting additional clinical research and developing policy recommendations for the “safe, ethical, and culturally informed implementation” of a psychedelic therapy program.

“The Legislature believes in addressing the mental health crisis affecting the State’s residents, particularly among veterans, first responders and trauma survivors,” SB 3199 reads. “Suicide remains the leading cause of preventable death, and the State must explore all safe and effective treatment options supported by scientific evidence.”

Given that the Federal Food and Drug Administration (FDA) has designated psilocybin and MDMA as breakthrough therapies in the treatment of serious mental health conditions, which may be subject to future control under the Controlled Substances Act (CSA), Hawaii’s legislation states that the state must “proactively prepare public health, clinical and research systems for safe and equitable implementation.”

The state Department of Health said in House committee testimony that it supports the bill, noting that in light of the FDA’s action on psychedelics, it is “prudent for Hawaii to assess research readiness, regulatory implications, workforce development and culturally informed implementation pathways” before any federal rescheduling of the substances.

The Governor’s Office of Wellness and Resiliency said the bill “has an important opportunity to begin paving a planned pathway for people who need access to life-saving treatments for trauma and other mental health issues.”

“A growing body of research demonstrates that breakthrough therapies (such as MDMA and psilocybin-assisted therapies) demonstrate high efficacy and positive clinical outcomes in the treatment of post-traumatic stress disorder, substance use disorders, end-of-life anxiety, eating disorders, depression, treatment-resistant, and additional conditions in terminally ill patients.”

Team members should include representatives from the State Department of Health (DOH), the Office of the Attorney General, the Office of Wellness and Resiliency (OWR), the University of Hawaii School of Medicine, and more.

Like the draft, the DOH would oversee the task force, an amendment approved by the House Health Committee last month makes the University of Hawaii John A. Burns School of Medicine (JABSOM) the responsible institution, and JABSOM’s nominee as the panel’s chairman.

The commission also adopted amendments suggested by the Department of Law Enforcement to say that its Division of Narcotics Enforcement — and not the Board of Pharmacy — would be responsible for changing the state’s scheduling of psychedelics after any federal reclassification, and to change the deadline for doing so from 90 days to 30 days.

Members note in their bill report that the state Agency for Health Planning and Development has expressed concern that psychedelics are illegal under federal law and that the task force should proceed with caution.

Finally, the panel made technical corrections for clarity, consistency, and style.

If ordered, it appears invoice would be It was first assembled in 2023 based on prior work by a separate psychedelic task force.With a similar goal of exploring avenues for therapeutic access in breakthrough drugs approved by the FDA such as psilocybin.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, Hawaii senators recently passed a bill to legalize low-dose, low-potency marijuanathe legislation did not advance the necessary steps before a crucial deadline, so it is dead for the year.

A separate marijuana legalization bill, SB 2421, that contained provisions under federal reform law or amendments to the state Constitution, was delayed for action. The Senate and House panels also delayed action on a measure to sell certain hemp-derived cannabinoid products.

These actions follow Senior lawmakers in the House indicated that proposals to legalize cannabis would not move forward In the 2026 session, citing the lack of sufficient support in their chamber.

Earlier this month, a Hawaii Senate committee unanimously approved legislation to allow patients immediately enter medical cannabis after submitting their recordsinstead of waiting for the cards to be delivered, as is the case under current legislation.

A Senate committee also adopted the resolutions Asking Congress to federally legalize marijuanasupport the state’s efforts to clean up people’s criminal records and take steps to make it easier for cannabis companies to access banking services.

Another Senate panel advanced separate resolutions urging the state attorney general and the health department to seek a waiver from the Drug Enforcement Administration (DEA). Hawaii is allowed to run its cannabis program without federal interference.

user photo Wikimedia/Mushroom Observer.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Missouri cannabis growers file class action against Good Day Farm

Published

5 hours ago

April 30, 2026

admin

CPC of Missouri-Smithville, LLC and GF Saint Mary LLC, licensed cannabis growers and manufacturers in Missouri, filed a lawsuit in the Circuit Court of Jackson County on behalf of independent wholesalers, alleging that Good Day Farm (GDF) and its network of conspiring companies and investors were harmed by an intentional, coordinated and unconstitutional scheme. The complaint alleges that the “GDF Cartel” illegally controls or manages the state’s share of dispensary licenses and uses that market power to manipulate Missouri’s $1.52 billion cannabis market for its own profit.

GDF and its co-conspirators allegedly built the cartel by arranging for third parties to invest in limited liability companies (LLCs) that then acquire additional dispensaries, cultivation and processing facilities, all of which are owned, operated or controlled by GDF. The result: The alleged cartel exercises effective control over at least 61 dispensaries, nearly triple the 22 allowed by the Missouri Constitution, with more than 10% of dispensary licenses “under substantially common control, ownership or management.” With 224 dispensaries currently licensed statewide, the alleged GDF Cartel controls more than one in four dispensary licenses in Missouri. But its influence is even greater, with alleged Cartel dispensaries accounting for more than 40% of wholesale cannabis in the state, giving it significant — and illegal — influence over all independent growers and manufacturers forced to sell through its network.

To avoid the Missouri Constitution’s 10% licensing limit and avoid regulatory oversight, the alleged cartel operates under five different brand names:

Good Day Farm (21 dispensaries),
CODES (20 dispensaries),
Green light (10 dispensaries),
Fresh Karma (6 dispensaries), and
3 Fifteen Primo (4 medications).

But they’re all part of a single, coordinated operation, the complaint says.

Purchase cannabis products from non-Cartel wholesalers at artificially depressed prices;
They supply their 61 dispensaries with the same products—mainly those produced by Cartel growers—significantly excluding products from independent wholesalers;
Force independent drug wholesalers to purchase the Cartel’s finished products as a condition for their wholesale products to be placed on the Cartel’s drug store shelves; and
Boycott non-cartel wholesalers who refuse to agree to anti-cartel demands.

Bob Hoffman, one of the attorneys leading the case, said: “The GDF Cartel is removing competition from the wholesale cannabis market and enriching itself with illegal profits through a counterproductive, clandestine business conspiracy. Missouri growers and manufacturers have been suffering under this scheme for a long time; many of them know something is wrong, but we don’t realize how the cartel has manipulated the market through this manipulation framework. Missourians to approve recreational cannabis in 2022 They voted for a fair and competitive market. Missouri licensed cannabis businesses that have suffered these practices should join us because they may be entitled to substantial damages.”

The complaint alleges the financial toll the Cartel has taken: Since the Cartel began illegal price-fixing, it has used its collective market power to lower wholesale prices by more than 20%, and continues to squeeze wholesalers and threaten the viability of their operations.

The unconstitutional complaint alleges that GDF knew its plan to build cartels could create legal risks for the company under the Constitution’s 10% licensing limit. The complaint quotes from a document provided by GDF to potential investors: “There can be no assurance that the Missouri Department of Cannabis Regulation will not dispute the number of marijuana dispensaries operated or supervised by the operator or its affiliates…”.

This action is brought on behalf of a putative class that includes all licensed independent wholesalers in Missouri that are not members of the alleged GDF Cartel for purposes of injunctive relief. Wholesalers who believe they have been financially harmed by the alleged Cartel’s practices should join the case because they may be entitled to substantial damages. The putative class is represented by the law firms of Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP.

Source: Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP

Cannabis News

State-Licensed Marijuana Businesses Can Now Apply For Federal Protections Using New DEA Form

Published

5 hours ago

April 30, 2026

admin

State licensee Medical marijuana companies can apply for federal protections In line with the Trump administration’s cannabis reprogramming process.

The Drug Enforcement Administration’s “Medical Marijuana Dispensary Registry Portal” went live Wednesday morning.

The move comes after the Justice Department announced that last week Marijuana Schedule I through III of the Controlled Substances Act (CSA), in stages.

Pursuant to an order signed by Attorney General Blanche, marijuana products regulated by a state medical cannabis license were immediately moved to Title III.

III. State-licensed medical cannabis dispensaries that wish to take advantage of the new legal protections and tax benefits that come with annexation status must first file an application with the DEA requesting information about their processes for storage, ordering, distribution, inventory, record keeping and other aspects of their business.

For each activity below, indicate whether the company has a standard operating procedure (SOP):

- the order
- receiving
- Inventories
- Marijuana storage
- security
- Distribution (including delivery services)
- to divide
- Destruction/Disposal
- Reporting Theft/Loss
- Due diligence (including provider/patient/professional verification)
- Corresponding Liability
- Record keeping”

The application asks about specific details of security measures such as vaults, safes, secure storage, access controls, alarm systems and on-site security personnel.

Applicants can choose whether to apply for administration of marijuana, marijuana extracts, or naturally derived delta-9 THC.

Currently, with only medical marijuana moving to Schedule III, the application asks potential registrants whether their businesses handle or provide recreational marijuana.

According to last week’s DOJ order, an expedited administrative hearing process will be held beginning June 29 to consider the broader cannabis reorganization.

The DEA application, meanwhile, also asks companies to submit information about their state’s cannabis licenses and to answer questions about their criminal and disciplinary history.

It also asks, “Has anyone involved in the ownership or operation of the business previously manufactured, distributed, and/or provided a controlled substance without a DEA registration authorizing such activity?”

Allegedly every illegal cannabis company operating in the state today has key employees who have done so, medical marijuana was a Schedule I substance whose manufacture, distribution and general distribution was not permitted by the DEA until just a few days ago.

Applicants must also list the suppliers from whom they plan to procure marijuana, and report whether they plan to repackage or relabel cannabis products.

They must also provide lists of people whose business they expect to have “access to controlled substances,” including their dates of birth, social security numbers, and drug-related criminal histories.

“Provide the following for each person you plan to acquire controlled substances:

- The name
- Title(s)
- date of birth
- Social Security number
- DEA registration numbers, if applicable
- State/territory permits to manufacture, distribute, dispense, or otherwise handle controlled substances
- Has this person been subject to one or more federal, state, territorial, or tribal disciplinary actions?
- Has this person been convicted of federal, state, territorial, tribal, or local offenses related to controlled substances?

There is also $794 per year the application fee, currently only payable through PayPal, although DEA ”expects to have additional payment methods in the coming weeks.”

Application fees are non-refundable.

Separately, the DEA has launched a new web page on its website that contains key information about the new federal rescheduling move for cannabis, including copies of Federal Register orders outlining the process for the amendment and the upcoming litigation.

Blanche’s reorganization order last week said that to comply with the international drug control treaty’s “requirement that a government agency act as the exclusive purchaser of cannabis production,” the DOJ is setting in motion a process by which the federal government technically buys from marijuana producers and then sells to them or related entities.

“Registered growers must store the crops in a DEA-accessible facility until that transaction is completed, and each grower’s registration must specify the area in which the grow is allowed,” he said.

“All manufacturers registered under this subsection shall establish a nominal price for the purchase of their marijuana crops. The Administration shall then purchase the entity’s crops at that price and resell the crops to the entity, or a related or supporting entity, at the same price plus the administrative fee calculated in section 1318.06(a)..”

Meanwhile, the US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after the reorganization announcement.

The reorganization will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

White House Press Secretary Karoline Leavitt said the administration is moving forward with the marijuana overhaul because Cannabis reform is “very popular” with voters and because doing so will help people who need access to the drug for medical purposes.

At the press event held in the Oval Office last week, President Donald Trump spoke about the medical benefits of marijuana.

“A lot of people are facing big problems, and that seems to be the best answer,” he said. “They’re very happy. So the reorganization begins, and that’s a big thing, the reprogramming.”

The president stated that his administration’s rescheduling of cannabis came about after his friend Howard Kessler told him about his use of medical marijuana.

“He had some medical difficulties, and it came about by chance, kind of,” he said. “He had to go through a lot of different medications, and he said this was the one that was so much better than anything else. And so he lived through that. He didn’t benefit from it, because now he lives much better from the perspective.”

“So we hope you don’t have to,” Trump said. “But if you must, I hear it’s the best of all alternatives.”

Separately, the president asked Congress to take action changing the law that threatens to federally recriminalize hemp-derived full-spectrum CBD products later this year

“We need to do this STRAIGHT and FAST, especially for those who have found CBD helping them,” he said in a social media post. “Also, I’m told it will help our BIG FARMERS that we love and will always be around.”

A few days ago, Trump denounced this Federal officials were “slowly” pursuing his cannabis warrant.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Klasmann-Deilmann announces management changes

Published

1 day ago

April 29, 2026

admin

After fifteen years of successful cooperation, managing director Moritz Böcking and the shareholders of Klasmann-Deilmann GmbH have mutually agreed to part ways. As of May 1, 2026, Moritz Böcking will hand over the position of managing director to Jan Astrup, who served as the company’s CEO in 2021/2022. Jan Astrup and Damian Ikemann will form the Board of Directors of the Klasmann-Deilmann Group from now on.

Klasmann-Deilmann thanks Moritz Böcking for his cooperation and the progress achieved in the transformation of the Klasmann-Deilmann Group. Moritz Böcking expanded Klasmann-Deilmann beyond the growing media business into new areas of commercial horticulture and promoted innovation and digitalization within the company. In addition, its achievements include the expansion of resources derived from renewable raw materials, as well as the acquisition of a subsidiary in Australia and production facilities in France and Canada, which operate in cooperation with external partners. He also significantly advanced Klasmann-Deilmann’s positioning as a global pioneer of sustainable development in the growing media industry, thereby making a decisive contribution to the company’s economic growth.

With Jan Astrup, Klasmann-Deilmann is getting an internationally experienced manager who has proven himself in the company and has extensive experience in raw materials, production, process optimization and technology. With the new CEO, raw materials and technology-driven areas for the substrate industry are now increasingly important at senior management level. Jan Astrup will strengthen the core commercial horticulture business and help develop the company for the future.

For more information:
Klasmann-Deilmann GmbH
(email protected)
www.klasmann-deilmann.com